Distal lung inflammation in asthma

Annals of Allergy, Asthma and Immunology

Volumn 89, Issue 2, 2002, Pages

  Sutherland, E Rand ^a   Martin, Richard J ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROFLUOROCARBON; CORTICOSTEROID; FLUORINATED HYDROCARBON; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; PRANLUKAST; PROPELLANT; ZAFIRLUKAST;

AIRWAY; ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DRY POWDER; HUMAN; INFLAMMATION; LUNG ALVEOLUS; MEDLINE; METERED DOSE INHALER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; TRANSBRONCHIAL BIOPSY;

EID: 0036706756     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1081-1206(10)61926-6     Document Type: Review

References (26)

1. Wagner EM, Liu MC, Weinmann GG, et al. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis 1990;141:584-588.
2. Irvin CG, Pak J, Martin RJ. Airway-parenchyma uncoupling in nocturnal asthma. Am J Respir Crit Care Med 2000;161:50-56.
3. Carroll N, Elliot J, Morton A, et al. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993;147:405-410.
4. Haley KJ, Sunday ME, Wiggs BR, et al. Inflammatory cell distribution within and along asthmatic airways. Am J Respir Crit Care Med 1998;158:565-572.
5. Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996;154: 1505-1510.
6. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990;142:434-457.
7. Kraft M, Martin RJ, Wilson S, et al. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999;159:228-234.
8. King GG, Muller NL, Pare PD. Evaluation of airways in obstructive pulmonary disease using high-resolution computed tomography. Am J Respir Crit Care Med 1999;159:992-1004.
9. Okazawa M, Muller N, McNamara AE, et al. Human airway narrowing measured using high resolution computed tomography. Am J Respir Crit Care Med 1996;154:1557-1562.
10. Goldin JG, McNitt-Gray MF, Sorenson SM, et al. Airway hyperreactivity: assessment with helical thin-section CT. Radiology 1998;208:321-329.
11. Montreal Protocol. The Montreal Protocol on substances that deplete the ozone layer. In: Final Act (Nairobi: UNEP, 1987). Federal Register, Washington, DC: 1994; 56276-56298.
12. Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest 2001;120(Suppl):89S-93S.
13. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung and Blood Institute, 1997. Report no 97-4051.
14. Laube BL. In vivo measurements of aerosol dose and distribution: clinical relevance. J Aerosol Med 1996;9(Suppl):S77-S91.
15. Leach CL. Enhanced drug delivery through reformulating MDIs with HFA propellants-drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory Drug Delivery V Proceedings. Buffalo Grove: Interpharm Press, 1996:133-144.
16. Vanden Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000;106:1209-1226.
17. Gross G, Thompson PJ, Chervinsky P, et al. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma. Chest 1999;115:343-351.
18. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12:1346-1353.
19. Adelroth E, Morris MM, Hargreave FE, et al. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986; 315:480-484.
20. Dahlen SE, Hedqvist P, Hammarstrom S, et al. Leukotrienes are potent constrictors of human bronchi. Nature 1980;288: 484-486.
21. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323:645-655.
22. Metters KM. Leukotriene receptors. J Lipid Mediat Cell Signal 1995;12:413-427.
23. 1 receptor. Nature 1999;399: 789-793.
24. Figueroa DJ, Breyer RM, Defoe SK, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001; 163:226-233.
25. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275:30531-30536.
26. Diamant Z, Sampson AP. Anti-inflammatory mechanisms of leukotriene modulators. Clin Exp Allergy 1999;29:1449-1453.